In a recent study that employed a microarray-based gene expression platform, we found that TGFB2 transcript, but not TGFB1 or TGFB3 levels were selectively amplified in primary tumor samples from 29 pediatric DIPG patients compared to normal samples and primary tumor samples from grade low-grade glioma patients [39]. This evidence concerns the gene TGFB2 and central nervous system cancer.